GC Biopharma Stock

GC Biopharma EBIT

The EBIT of GC Biopharma (006280.KS) as of Aug 8, 2026 is 32.11 B KRW. In the previous year, EBIT was 34.44 B KRW — a change of -6.76% (lower).

EBIT

32.11 BKRW

YoY

-6.76%

Last updated:

In 2026, GC Biopharma's EBIT was 32.11 B KRW, a -6.76% increase from the 34.44 B KRW EBIT recorded in the previous year.

The GC Biopharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B KRW)
Date
EBIT (B KRW)
Jan 1, 2020
50.25 base
Jan 1, 2021
73.66 base
Jan 1, 2022
81.26 base
Jan 1, 2023
34.44 base
Jan 1, 2024
32.11 base
Jan 1, 2025 (e)
76.84 base
Jan 1, 2027 (e)
81.88 base
Jan 1, 2028 (e)
88.39 base
YEAREBIT (B KRW)
2028 est 88.39
2027 est 81.88
2025 est 76.84
2024 32.11
2023 34.44
2022 81.26
2021 73.66
2020 50.25
2019 41.68
2018 50.15
2017 90.30
2016 78.45
2015 91.68
2014 96.97
2013 78.81
2012 74.36
2011 85.39
2010 153.05
2009 119.39
2008 67.93
2007 58.45
2006 54.86
2005 33.96
Access this data via the Eulerpool API

GC Biopharma Revenue

GC Biopharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.50 T KRW
50.25 B KRW
81.05 B KRW
Jan 1, 2021
1.54 T KRW
73.66 B KRW
123.21 B KRW
Jan 1, 2022
1.71 T KRW
81.26 B KRW
65.45 B KRW
Jan 1, 2023
1.63 T KRW
34.44 B KRW
-26.63 B KRW
Jan 1, 2024
1.68 T KRW
32.11 B KRW
-26.28 B KRW
Jan 1, 2025 (e)
1.99 T KRW
76.84 B KRW
26.16 B KRW
Jan 1, 2027 (e)
2.12 T KRW
81.88 B KRW
59.31 B KRW
Jan 1, 2028 (e)
2.29 T KRW
88.39 B KRW
92.15 B KRW

GC Biopharma Margins

GC Biopharma stock margins

The GC Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GC Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GC Biopharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
29.29 %
3.34 %
5.39 %
Jan 1, 2021
33.85 %
4.79 %
8.01 %
Jan 1, 2022
34.00 %
4.75 %
3.82 %
Jan 1, 2023
29.79 %
2.12 %
-1.64 %
Jan 1, 2024
28.69 %
1.91 %
-1.56 %
Jan 1, 2025 (e)
28.69 %
3.86 %
1.32 %
Jan 1, 2027 (e)
28.69 %
3.86 %
2.80 %
Jan 1, 2028 (e)
28.69 %
3.86 %
4.03 %

GC Biopharma Stock analysis

What does GC Biopharma do? GC Biopharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing GC Biopharma's EBIT

GC Biopharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of GC Biopharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

GC Biopharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in GC Biopharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about GC Biopharma stock

EBIT of GC Biopharma is 32.11 B KRW in 2026.

EBIT of GC Biopharma changed from 34.44 B KRW to 32.11 B KRW, representing a -6.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT GC Biopharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's GC Biopharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — GC Biopharma

All Key Metrics — GC Biopharma